Key Takeaways
- Record quarter, conservative guide: Q4 delivered the highest EBITDA and PAT to date, yet management guided FY25 EBITDA growth at a moderate 10–12%, citing market volatility and a preference for conservative commitments.
- CDMO/CMO is the margin engine: The segment was the highest contributor to incremental EBITDA improvement, and management is projecting 30–35% growth over the next 2–3 years, driven by a pipeline of 19 products under development.
- A massive CAPEX cycle is underway: A ₹600 crore FY25 CAPEX plan targets three big projects: the Atali greenfield site, Xanthine capacity expansion, and a solar power plant, setting the stage for growth from FY26.
- Xanthine prices have bottomed, but the backward integration plant sits idle: Spot market prices have stabilized, but the plant built for raw material independence is not operating because Chinese imports remain cheaper, delaying a key margin lever.
- What to watch next quarter: The pace of Xanthine expansion approvals, any update on the ₹150 crore brownfield CAPEX freeze, and whether the Vapi semi-commercial block begins seeding projects as planned in Q1.
CDMO/CMO: The Growth Engine
- Portfolio profile: 80–90% of the CMO portfolio is in KSM and RSM, with a few APIs. The business is campaign-based and multi-stage, so quarterly revenue fluctuations are expected.
- Pipeline depth: The company is working with 21 already commercialized products and 19 products under development. Not all 21 are manufactured year-round, but they are viable projects in the commercial stage.
- Engagement stage: The company largely works in the late clinical and commercial phases, not preclinical. Most projects are entered in the middle segment by partnering with innovators, and large growth happens when projects pass through clinical phase approvals.
- Growth trajectory: 12 new projects were added this year. These projects normally take 2–3 years to fully grow, and as they do, revenue will increase.
- Blockbuster potential: Management declined to identify specific molecules with potential to scale to ₹200–300 crores, stating only that "there are some good potential products."
Hetal Gogri Gala: "Typically, all our customers are looking at us as a sustainable partner and to have a significant portfolio on their purchasing list, we find it, it is important for us to expand and be a world standard capacity for Xanthine business and that is a reason why we are expanding."
Xanthine: Price Bottom, Capacity Top-Up
- Price-volume dynamics: Prices declined drastically by around 20–25%, while capacities went up by around 12–15%. Raw material prices also reduced, explaining top-line de-growth despite volume growth.
- Pricing outlook: Spot market prices have bottomed out, and no further price decline is expected based on current market understanding.
- Current utilization: Running at 90% capacity. The endeavor is to increase to 95% or more, but brownfield modifications to existing assets will cause some disruptions, making it a "mixed bag."
- Expansion plan: A brownfield expansion from 5,000 to 9,000 metric tonnes is underway, with a 12–15 month completion timeline. The CAPEX amount is still being frozen but is around ₹150 crore.
- Ramp-up timeline: Management expects to achieve capacity utilization within two years of the expansion becoming active, targeting FY27.
- New end-uses: The expanded capacity will enter the regulated pharma space (CEP and USDMF) for Caffeine and Theophylline, alongside increased food and beverage volumes. Pharma offers better realization but lower volumes.
- Backward integration on hold: The manufacturing asset for raw material independence is operationally ready but not being continuously operated because current market prices from China are very low. The plant will be operated only if prices go above a certain threshold.
Rashesh Gogri: "No, that manufacturing asset is operationally ready. But looking at the current manufacturing costs and the prices of product availability from China, we are not opting to continuously operate that plant, looking at very lower pricing availability from the market."
CAPEX Program: Building for FY26
- FY25 CAPEX: Total CAPEX of around ₹600 crores, with three big projects: Atali greenfield (₹300 crores), Xanthine capacity expansion at Tarapur (₹130–180 crores, still being finalized), intangible asset development (₹40–50 crores), and a solar project (₹80–90 crores).
- Atali greenfield: A large 80-acre site in Gujarat where 10 blocks of ₹100+ crore CAPEX can be placed. The concept is a large site that doesn't require re-audit or re-approvals from innovators or regulatory authorities, rationalizing manpower cost through consolidation. Commissioning is expected by Q4 FY25.
- Atali CAPEX spent: ₹30 crore of the ₹375 crore Atali CAPEX was spent in FY24.
- Atali asset turnover: Management walked back a previously mentioned 1.6 to 2 times asset turn target, saying it "needs to be revisited" and "there is some confusion for that number." The current endeavor is to get +1 asset turn, or 1 to 1.2.
- Vapi semi-commercial block: Nearing completion and expected to become operational in Q1 FY25. It will enable feeding projects for early customer requirements up to 100 kg, but is not expected to have a material impact on top or bottom line.
- Solar power plant: An ₹80–90 crore project approved during FY24, estimated to fulfill one-third of power requirements and reduce overall manufacturing cost. Expected to be operational by the last quarter of FY25.
Rashesh Gogri: "It's a very large land parcel that we have, we have close to 80 acre land and where we can do current expansion kind of 10 expansions. So, we can put 10 blocks of +100 crore CAPEX in the same site."
Margins & Profitability
- Gross margin philosophy: Management tracks absolute profit numbers rather than percentage margins because percentage is a function of raw material prices. When RM prices go down, the advantage is passed to customers via pass-through mechanisms.
- Gross margin outlook: Expect to maintain close to 50% gross margin on an annual consolidated basis. Standalone gross margins of ~55% will rationalize to around 50% over time.
- OPEX increase in Q4: Higher OPEX was driven by a write-down of R&D projects (almost ₹6.5 crores) and an increase in freight in line with higher sales. Year-on-year, OPEX barely grew by ₹4 crores.
- R&D write-off: An R&D project of ₹6.76 crores was written off, a practice done every quarter for projects the company decides not to pursue due to insufficient market or other reasons.
- Tax rate anomaly: Q4 tax rate of 32% and full year 28% (vs a normalized 25–25.5%) was due to the operationalization and capitalization of the new R&D center in Maharashtra. R&D gets a 100% tax deduction, but in the books it came in Q4, creating the difference.
- Deferred tax liabilities: Increased from ₹80 crore to ₹107 crore.
- Intangible assets: Other intangible assets (₹17 crore) and intangible assets under development (₹58 crore) are capitalizations of R&D expenses (salaries of scientists, consumables, raw materials, other direct attributable costs) once products are commercialized.
- Working capital: Management is trying to keep the absolute working capital amount at the current level while bringing the number of days down.
R&D and New Capabilities
- New R&D center: Being used to establish high-barrier research segments including peptides, flow chemistry, and other newer chemistry.
- Timeline to maturity: It will take two to three years to gain confidence and have more skill sets and manufacturing assets to develop peptides, ADCs, sterile, and other high-barrier segments.
- Raw material facility repurposing: The primary raw material facility for Xanthine is currently non-operating. The company is trying to develop new value-added projects based on that capability.
- China Plus One strategy: Customers are looking at China Plus One as a very important criterion, and the company's expansion is driven by this. The company offers customers non-dependence on China and green, sustainable manufacturing assets with a better total carbon footprint than competitors.
Piyush Lakhani: "the advantage that we are giving to our customers is completely non-dependence and also the green and sustainable manufacturing assets that we have, with the green power that we are now investing in and our overall total carbon footprint also much better than the other competitors."
Segment Performance
| Segment | Trend | Commentary |
|---|---|---|
| CDMO/CMO | ▲ Strong growth | Highest contributor to incremental EBITDA; 21 commercial products, 19 under development; projecting 30–35% growth over 2–3 years. |
| API & Intermediates | ▲ Improving | Most validations completed and DMS approved; better growth than the 10% seen last year is expected from this year onwards. |
| Xanthine | ▼ Price pressure | Prices declined 20–25%, bottomed out; capacity utilization at 90%; expansion to 9,000 MT underway. |
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EBITDA growth | Approximately 10% to 12% growth | FY25 |
| Long-term annual growth | Around 15% | Next two years |
| CDMO/CMO growth | 30–35% growth | Next 2–3 years |
| Gross margin | Close to 50% on annual consolidated basis | Ongoing |
| Standalone EBITDA margin | 20% to 22% | Ongoing |
| Atali greenfield commissioning | Plant operational | Q4 FY25 |
| Vapi semi-commercial block | Operational, revenue from Q2 FY25 | Q1 FY25 |
| Solar power plant | Operational, fulfilling 1/3 of power needs | Last quarter FY25 |
| Xanthine brownfield expansion | 5,000 to 9,000 MT capacity | 12–15 months to complete; FY27 for optimum utilization |
| New capacity sales contribution | Sales from new additional capacity | FY26 onwards |
| High-barrier R&D segments | Peptides, ADCs, sterile capabilities | 2–3 years to gain confidence |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| Consolidated EBITDA | ₹117.5 cr, +23% QoQ and +47% YoY |
| Consolidated PAT | ₹65.3 cr, +24% QoQ and +52% YoY |
| Standalone EBITDA | ₹107.3 cr, +22% QoQ and +40% YoY |
| Standalone PAT | ₹63 cr, +31% QoQ and +58% YoY |
| Consolidated EBITDA (full year FY24) | ₹386 cr, +13% YoY |
| Consolidated PAT (full year FY24) | ₹217 cr, +12% YoY, EPS ₹22.9 |
| Standalone EBITDA (full year FY24) | ₹346.2 cr, +12% vs FY23 |
| Standalone PAT (full year FY24) | ₹201 cr, +17% YoY, EPS ₹22.1 |
| Return on capital employed (FY24) | 18%, up from 17.7% in FY23 |
| Consolidated net debt to equity | 0.14% as on March 31, 2024 |
| Standalone gross margin | ~55% in Q4 |
| Consolidated gross margin | ~50% in Q4 |
| EBITDA growth guidance for FY25 | 10% to 12% |
| Long-term annual growth target | ~15% for the next two years |
| Standalone EBITDA margin guidance | 20% to 22% |
| Xanthine derivatives revenue share | 44% of Q4 turnover |
| API and Intermediates revenue share | 37.6% of Q4 turnover; regulated markets 54%, rest of world 34%, non-regulated 12% |
| CDMO/CMO revenue share | 18.4% of Q4 turnover |
| CDMO/CMO Q4 sales | ~₹76 cr, up from ~₹53 cr (per an analyst's math) |
| CDMO/CMO full year FY24 sales | ₹177 cr, up from ~₹100 cr in FY23 |
| CDMO/CMO projects | 40 projects with 16 customers; 21 commercial, 19 under development |
| CDMO/CMO projects added in FY24 | 12 new projects |
| Xanthine plant capacity utilization | 90% |
| Other plants capacity utilization | 85% |
| Xanthine capacity expansion target | 750 metric tonnes per month |
| Xanthine capacity debottlenecking | From 5,000 to 9,000 metric tonnes |
| Xanthine price decline | 20% to 25% YoY |
| Xanthine volume growth | 12% to 15% YoY |
| Total CAPEX planned for FY25 | ~₹600 cr |
| Atali greenfield project CAPEX | ~₹375 cr (apart from land cost of ₹50 cr) |
| Solar project CAPEX | ₹80-90 cr in FY25 |
| Xanthine brownfield expansion CAPEX | ₹130-180 cr (still being finalized) |
| Intangible asset development spend (FY25) | ₹40-50 cr |
| R&D project write-off in Q4 | ₹6.5 cr |
| Normalized tax rate | 25% to 25.5% of PBT |
| Final dividend recommended | ₹1 per share (in addition to interim dividend) |